NeuraStasis is developing StrokeGuard: a first-of-its-kind wearable emergency device designed to preserve brain tissue during the critical window between stroke onset and definitive treatment.
In stroke, Time is Brain. Current treatments depend on reaching a capable hospital before irreversible damage sets in, and for many patients, that gap is devastating.
The ischemic core rapidly consumes surrounding salvageable penumbra, causing irreversible brain damage.
Reaching a capable facility adds hours of untreated time. No neuroprotective intervention exists during transit.
Less than half the global population has immediate access to definitive stroke treatment during the most critical window.
The global economic burden of stroke exceeds $890 billion annually, with over $111 billion in the US alone. The lifetime cost per stroke patient averages over $140,000, yet no approved device exists to protect the brain during the pre-hospital window.
Deployed like a cardiac AED and designed to travel with patients as a wearable emergency device during the critical transport window.
StrokeGuard uses non-invasive electrical stimulation of the trigeminal nerve to trigger the body's own cerebrovascular reflexes, promoting increased collateral blood flow to at-risk brain tissue to give patients and providers more time to act.
StrokeGuard is designed to increase cerebral blood flow by lowering cerebrovascular resistance, without systemic hypotension or pharmaceutical blood thinners. It is intended to act before and bridge to definitive treatment such as thrombolysis or thrombectomy, and to be safe for pre-hospital use where stroke type may not yet be confirmed.
StrokeGuard is wall-mounted in facilities and ambulances, modeled on the proven cardiac AED paradigm. It is applied to the patient's forehead in seconds by any first responder.
External electrodes contact forehead.
No surgical intervention.
Applied like a headband. Travels with the patient through the clinical workflow.
Available in ambulances and community settings for rapid deployment from the earliest moments of stroke onset.
Static, open-loop delivery cannot overcome biological habituation or patient variability. This is the reason historical neuroprotection approaches have failed. StrokeGuard is built on a physical AI architecture that continuously senses each patient's hemodynamic state and adapts stimulation to deliver lasting neuroprotection.
Multi-wavelength near-infrared source-detector pairs continuously monitor regional cerebral oxygen saturation in watershed regions.
Proprietary physiological closed-loop algorithm dynamically adjusts stimulation parameters in real time.
Precisely calibrated electrical pulses delivered non-invasively through forehead electrodes.
We partner with clinical institutions, EMS systems, device manufacturers, and investors who share our mission to bring neuroprotection to patients.